Phosphatemic Effect of Cinacalcet in Kidney Transplant Recipients With Persistent Hyperparathyroidism

American Journal of Kidney Diseases

Volumn 52, Issue 6, 2008, Pages 1151-1157

  Serra, Andreas L ^a,b   Wuhrmann, Claudia ^b   Wüthrich, Rudolf P ^a,b  

^a PSI   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cinacalcet; fibroblast growth factor 23 (FGF 23); hyperparathyroidism; parathyroid hormone (PTH); phosphorus; renal transplantation

Indexed keywords

BICARBONATE; CALCIUM; CINACALCET; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE;

ACID BASE BALANCE; ADULT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ABSORPTION; MALE; PH; PHOSPHATE BLOOD LEVEL; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RECIPIENT; TREATMENT RESPONSE; URINARY EXCRETION;

FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES;

EID: 56049108329     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.08.012     Document Type: Article

References (29)

1. Kempson S.A., Lotscher M., Kaissling B., et al. Parathyroid hormone action on phosphate transporter mRNA and protein in rat renal proximal tubules. Am J Physiol 268 (1995) F784-F791
2. Ohkido I., Segawa H., Yanagida R., et al. Cloning, gene structure and dietary regulation of the type-IIc Na/Pi cotransporter in the mouse kidney. Pflugers Arch 446 (2003) 106-115
3. Shimada T., Mizutani S., Muto T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98 (2001) 6500-6505
4. Shimada T., Yamazaki Y., Takahashi M., et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289 (2005) F1088-F1095
5. Kobayashi K., Imanishi Y., Miyauchi A., et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 154 (2006) 93-99
6. Yamashita H., Yamashita T., Miyamoto M., et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol 151 (2004) 55-60
7. Gutierrez O., Isakova T., Rhee E., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16 (2005) 2205-2215
8. Larsson T., Nisbeth U., Ljunggren O., et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64 (2003) 2272-2279
9. Shigematsu T., Kazama J.J., Yamashita T., et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44 (2004) 250-256
10. Pande S., Ritter C.S., Rothstein M., et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 104 (2006) p23-p32
11. Evenepoel P., Naesens M., Claes K., et al. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7 (2007) 1193-1200
12. Bhan I., Shah A., Holmes J., et al. Post-transplant hypophosphatemia: Tertiary 'hyper-phosphatoninism'?. Kidney Int 70 (2006) 1486-1494
13. Fox J., Lowe S.H., Petty B.A., et al. NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 290 (1999) 473-479
14. Serra A.L., Savoca R., Huber A.R., et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 22 (2007) 577-583
15. Serra A.L., Schwarz A.A., Wick F.H., et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 20 (2005) 1315-1319
16. El-Amm J.M., Doshi M.D., Singh A., et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 83 (2007) 546-549
17. Serra A.L., Braun S.C., Starke A., et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant 8 (2008) 803-810
18. Srinivas T.R., Schold J.D., Womer K.L., et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 1 (2006) 323-326
19. Kruse A.E., Eisenberger U., Frey F.J., et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 20 (2005) 1311-1314
20. Szczech L.A. The impact of calcimimetic agents on the use of different classes of phosphate binders: Results of recent clinical trials. Kidney Int Suppl 90 (2004) S46-S48
21. Szwarc I., Argiles A., Garrigue V., et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 82 (2006) 675-680
22. Charytan C., Coburn J.W., Chonchol M., et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46 (2005) 58-67
23. Geller J.L., Khosravi A., Kelly M.H., et al. Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22 (2007) 931-937
24. Isakova T., Gutierrez O., Shah A., et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 19 (2008) 615-623
25. Kawata T., Imanishi Y., Kobayashi K., et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18 (2007) 2683-2688
26. Sato T., Tominaga Y., Ueki T., et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44 (2004) 481-487
27. Imel E.A., Peacock M., Pitukcheewanont P., et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91 (2006) 2055-2061
28. Moe S.M., Chertow G.M., Coburn J.W., et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67 (2005) 760-771
29. Carpenter T.O., Ellis B.K., Insogna K.L., et al. Fibroblast growth factor 7: An inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90 (2005) 1012-1020